Commentary on a phase III trial of Bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial

Preeta Tyagi, Axel Grothey

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Commentary on a phase III trial of Bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences